Como investigar el uso de medicamentos por los consumidores

Esta disponible el documento de mas de 100 paginas “Como investigar el uso de medicamentos por los consumidores” de Anita Hardon, Catherine Hodgkin y Daphne Fresle. Edicion conjunta de de la OMS y la Universidad de Amsterdam . Febrero 2005 (ahora en la version en idioma castellano).

El documento original esta disponible en:

http://www.who.int/entity/medicines/publications/WHOEDMPAR2004.2spa.pdf

una version un poco mas liviana (500 kb)  en Fundacion Femeba
http://www.femeba.org.ar/fundacion/quienessomos/Novedades/uso_medicamentos_comunidad_oms_es.pdf

Martin Canas
GAPURMED
La Plata (Argentina)
macanas@netverk.com.ar

National Guidelines Clearinghouse

American College of Radiology. Incidentally discovered adrenal mass.American Urological Association Education and Research, Inc. Guideline for the management of clinically localized prostate cancer: 2007 update.

Association of Coloproctology of Britain and Ireland. Guidelines for the management of colorectal cancer.

Finnish Medical Society Duodecim. Acne.

Finnish Medical Society Duodecim. Benign prostatic hyperplasia.

University of Texas at Austin School of Nursing, Family Nurse Practitioner Program. Evaluation and management of obstructing cerumen.

University of Texas at Austin School of Nursing, Family Nurse Practitioner Program. Evaluation, management and treatment of sunburn in adults.

University of Texas at Austin School of Nursing, Family Nurse Practitioner Program. Management of human bite wounds.

Cribado en enfermedad celiaca

Articulo en PDF

No hay evidencia de que los IBP incrementen el riesgo de eventos cardiacos

La FDA ha concluído que el uso a largo plazo de los inhibidores de la bomba de protones (IBP) omeprazol y esomeprazol no está asociado con un riesgo incrementado de problemas cardiacos.En Agosto, la FDA había publicado un reporte preliminar que al parecer estas drogas no incrementaban el riesgo cardiaco. Ahora, después de finalizar su revisión de la evidencia, la agencia a reafirmado su postura.

FDA informed healthcare professionals of the issuance of the Agency’s follow-up communication regarding its review of safety data for the drugs omeprazole and esomeprazole that raised concerns about a potential increased risk of heart problems for patients treated with these drugs. The Agency conducted a comprehensive review of the data from two studies that were submitted to FDA. FDA continues to believe that long-term use of omeprazole or esomeprazole is not likely to be associated with an increased risk of heart problems and recommends that healthcare providers continue to prescribe and patients continue to use these products in the manner described in the labeling for the two products. See the “Update of Safety Review” for information regarding the two studies that were reviewed.

Read the complete MedWatch 2007 Safety Summary including a link to the follow-up FDA communication regarding this issue at:

http://www.fda.gov/medwatch/safety/2007/safety07.htm#Omeprazole

Boletin de Farmacos: noviembre 2007

Noviembre 2007

vol 10 (5)